Joshua M. Epstein
#174,417
Most Influential Person Now
Joshua M. Epstein's AcademicInfluence.com Rankings
Joshua M. Epsteinbiology Degrees
Biology
#14445
World Rank
#18199
Historical Rank
Molecular Biology
#2467
World Rank
#2506
Historical Rank
Download Badge
Biology
Why Is Joshua M. Epstein Influential?
(Suggest an Edit or Addition)Joshua M. Epstein's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The molecular classification of multiple myeloma. (2006) (1012)
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. (2006) (839)
- IRF4 addiction in multiple myeloma (2008) (622)
- Total therapy with tandem transplants for newly diagnosed multiple myeloma. (1999) (617)
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial (2017) (585)
- Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. (2001) (553)
- Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression (2001) (538)
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. (2009) (454)
- Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. (2007) (374)
- Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. (2000) (340)
- Plasma cell myeloma--new biological insights and advances in therapy. (1989) (340)
- Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity (2002) (325)
- Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 (2007) (321)
- Interleukin-6 prevents dexamethasone-induced myeloma cell death. (1994) (299)
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing (2017) (249)
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. (2008) (246)
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. (2008) (237)
- Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. (1999) (225)
- Curing myeloma at last: defining criteria and providing the evidence. (2014) (204)
- Soluble syndecan-1 promotes growth of myeloma tumors in vivo. (2002) (200)
- Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. (1998) (193)
- High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. (2007) (181)
- High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. (2000) (181)
- The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. (1999) (180)
- Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma (2006) (174)
- Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. (2017) (166)
- P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. (1989) (163)
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. (2016) (162)
- Markers of multiple hematopoietic-cell lineages in multiple myeloma. (1990) (160)
- Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. (2006) (157)
- Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen (1993) (153)
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. (2011) (150)
- Cancer and the Microenvironment (2004) (145)
- VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma (2008) (142)
- Heparanase promotes the spontaneous metastasis of myeloma cells to bone. (2004) (142)
- Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. (2000) (141)
- Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients (2015) (133)
- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. (2007) (132)
- Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. (2006) (129)
- Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. (2003) (129)
- Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma (2008) (125)
- Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. (2007) (122)
- Glutamine Enhances Selectivity of Chemotherapy Through Changes in Glutathione Metabolism (1995) (116)
- Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. (1988) (110)
- Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations (1998) (107)
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. (2008) (105)
- Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells (1993) (100)
- Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling (2007) (100)
- Deletion of the retinoblastoma gene in multiple myeloma. (1994) (98)
- Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma (2018) (97)
- Highly activated and expanded natural killer cells for multiple myeloma immunotherapy (2012) (95)
- The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. (2007) (89)
- The Esterase Activity in Megaloblasts, Leukaemic and Normal Haemopoietic Cells (1968) (88)
- Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. (1993) (85)
- Differentiation stage of myeloma plasma cells: biological and clinical significance (2017) (84)
- Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. (2010) (83)
- Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. (1996) (82)
- The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. (1998) (81)
- Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) (2020) (79)
- Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. (2016) (78)
- Human Placenta‐Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone (2011) (74)
- TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3 (2009) (74)
- Novel and Detrimental Effects of Lipopolysaccharide on In Vitro Generation of Immature Dendritic Cells: Involvement of Mitogen-Activated Protein Kinase p38 1 (2003) (73)
- Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS) (2005) (72)
- Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data (2013) (71)
- Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat (2015) (67)
- Antimyeloma efficacy of thalidomide in the SCID-hu model. (2002) (67)
- Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease (2007) (66)
- The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. (2018) (65)
- Characterization of Wnt/β‐catenin signalling in osteoclasts in multiple myeloma (2010) (63)
- Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 (2015) (62)
- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease (2013) (60)
- An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. (2012) (58)
- Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival (2006) (52)
- Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside (1984) (52)
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma (2017) (52)
- Advances in Biology and Therapy of Multiple Myeloma (2013) (51)
- Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics (2007) (49)
- Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma. (1988) (49)
- Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. (1998) (49)
- Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120) (2015) (47)
- Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. (1993) (46)
- MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. (2016) (46)
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. (2014) (44)
- Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. (1992) (44)
- Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma (2013) (43)
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. (2013) (41)
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. (2014) (41)
- Consequences of interactions between the bone marrow stroma and myeloma. (2003) (40)
- Myeloma and bone disease: "the dangerous tango". (2006) (39)
- Biology and therapy of multiple myeloma in 1996. (1997) (38)
- Prediction of cytogenetic abnormalities with gene expression profiles. (2012) (38)
- NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. (2011) (37)
- Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma (2012) (36)
- Myeloma phenotype: clues to disease origin and manifestation. (1992) (36)
- The Arkansas approach to therapy of patients with multiple myeloma. (2007) (35)
- Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells (2000) (35)
- Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis (2014) (34)
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease (2017) (33)
- β2‐microglobulin as a negative growth regulator of myeloma cells (2002) (29)
- Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia (2004) (29)
- Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma (2013) (29)
- Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) (2018) (28)
- Biomarkers that Discriminate Multiple Myeloma Patients with or without Skeletal Involvement Detected Using SELDI-TOF Mass Spectrometry and Statistical and Machine Learning Tools (2006) (28)
- Proteasome inhibitors and bone disease. (2012) (27)
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype (2017) (25)
- MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma (2018) (24)
- CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. (2014) (24)
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma (2018) (24)
- Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma (2017) (23)
- The SCID-hu myeloma model. (2005) (22)
- In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes (2014) (21)
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma (2016) (21)
- Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 (2012) (19)
- Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma. (2014) (18)
- 2Biological aspects of multiple myeloma (1995) (16)
- Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2'-deoxycoformycin. (1986) (15)
- Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. (1984) (13)
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes (2018) (13)
- IP3, IP3 receptor, and cellular senescence (2000) (13)
- Myeloma stem cell phenotype. Implications for treatment. (1997) (13)
- Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis? (2019) (12)
- Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells (2014) (12)
- Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy. (1981) (12)
- Myeloma Bone Disease (2009) (11)
- A Comparison of Two Methods for Determining the Sensitivity of Human Myeloid Colony‐forming Units to Cytosine Arabinoside (1981) (10)
- Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants (2016) (10)
- Total Therapy 3 (TT3) Incorporating VelcadeR (V) Intro Upfront Management of Multiple Myeloma (MM): Comparison with TT2 + Thalidomide (T). (2005) (9)
- Biological aspects of multiple myeloma. (1995) (9)
- An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups. (2006) (8)
- Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients (2012) (8)
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance (2015) (8)
- A method for obtaining human bone marrow specimens enriched for myeloblasts and promyelocytes. (1979) (8)
- Multiple myeloma--recent developments in molecular and cellular biology. (1995) (8)
- Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression (2015) (8)
- Myeloma-Derived Exosomes and Soluble Factors Suppress Natural Killer Cell Function (2016) (8)
- The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse (2016) (8)
- Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response. (2004) (8)
- A non-clonogenic assay for the determination of the sensitivity of leukemic cells to chemotherapeutic agents. (1983) (7)
- The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma (2015) (7)
- Circulating B lymphocytes in multiple myeloma patients contain an autocrine IL-6 driven pre-myeloma cell population. (1992) (7)
- A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3 (2016) (6)
- Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival. (2005) (6)
- Effects of cytosine arabinoside on DNA synthesis and the clonogenicity of RF/UN murine myeloid leukemia cells. (1980) (6)
- Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma (2016) (6)
- Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse (2017) (6)
- Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 (2008) (5)
- FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls. (2004) (5)
- New insight into myeloma lytic bone disease (2003) (5)
- IP(3), IP(3) receptor, and cellular senescence. (2000) (5)
- Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120) (2016) (5)
- Genotypic and phenotypic characteristics of multiple myeloma (1988) (5)
- Senescent fibroblasts as feeder cells for lymphoid cell cloning. (1996) (4)
- Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy (2008) (4)
- Protection of normal hematopoietic stem cells from the toxicity of purine base analogs: in vivo application. (1984) (4)
- PET and PET/CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias (2006) (4)
- Specific Exosomal microRNA Are Differentially Expressed Between High and Low-Risk Myeloma Suggesting They Are Pathogenically Important (2015) (4)
- MRI-Detectable Focal Lesions (FL) in Multiple Myeloma (MM) at Relapse Frequently Involve Novel Sites Not Involved at Diagnosis. (2004) (4)
- Carfilzomib Induces Differentiation of Mesenchymal Stromal Cells Toward Osteoblast Via Activation of β-Catenin/TCF Signaling (2012) (4)
- Multiple Myeloma Evolves from a Malignant Hematopoietic Stem Cell (1991) (3)
- Multiple myeloma: biology and therapy (2005) (3)
- Curing Multiple Myeloma (MM) with Total Therapy (TT) (2014) (3)
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients (2016) (3)
- Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? (2016) (3)
- The Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature, Resilient, Apoptosis-Resistant Phenotype. (2004) (3)
- Effects of cytosine arabinoside on unseparated bone marrow and peripheral blood cells and on specimens enriched for myeloblasts and promyelocytes. (1980) (3)
- Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment (2016) (3)
- Going with the flow, and beyond, in myeloma. (2008) (3)
- Constitutively activated STAT3 in myeloma cells (1996) (3)
- Clonal Growth of Leukaemic Cells In Vitro (1981) (2)
- Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity (2013) (2)
- Myeloma Exosomes Prime the Microenvironment to Support Survival and Growth of Myeloma Cells (2016) (2)
- Complete Response (CR) with Total Therapy 2 (TT2) for Multiple Myeloma (MM): Low Frequency in Case of Prior MGUS without Adverse Consequences for Survival - Yet Critical for Disease Control in Presumed “De Novo” MM. (2005) (2)
- MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma (2013) (2)
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing (2017) (2)
- Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression (2017) (2)
- Rapid Response to Treatment of Multiple Myeloma Detected with FDG PET Scanning in Multiple Myeloma - Early Results from Total Therapy III. (2004) (2)
- Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order (2012) (2)
- [Therapy of acute nonlymphocytic leukemia: 2. Biological characteristics and prediction of response]. (1979) (2)
- Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival (2013) (2)
- Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis (2011) (2)
- Effects of busulfan on the DNA of HL-60 cells as a drug sensitivity assay. (1986) (2)
- Myeloma Cell Interaction with Mesenchymal Stem Cells: Heterogeneity of Myeloma Cell Survival and Gene Expression Studies (2008) (2)
- Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma (2015) (2)
- High Frequency of Molecular Remissions (m-CR) in Multiple Myeloma Patients Achieving a Hematologic Complete Remission (CR) on Total Therapy II (TT-2). (2004) (2)
- The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition (2016) (2)
- DNA Flow Cytometry and Metaphase Cytogenetics Can Predict Progression of Asymptomatic Monoclonal Gammopathies (AMG) to Symptomatic Multiple Myeloma (MM). (2012) (2)
- Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma (2019) (2)
- Secreted Frizzled-Related Protein-3 (sFRP3) Is Produced by Myeloma Cells and Augments Wnt3a-Induced Differentiation of Mesenchymal Stem Cells and OPG Production in Osteoblasts (2011) (2)
- Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups (2019) (1)
- Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM) (2015) (1)
- The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells (2017) (1)
- Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance (2018) (1)
- Pharmacogenomic Study of Carfilzomib in Relapsed/Refractory Multiple Myeloma Suggests That Carfilzomib Is a More Potent Proteasome Inhibitor Than Bortezomib (2012) (1)
- Gene Expression Profiling-Based Risk Stratification Scores In Multiple Myeloma Can Be Highly Sensitive Towards Sample Preparation (2013) (1)
- Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines (2015) (1)
- Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma. (2005) (1)
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma (2016) (1)
- Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse. (2005) (1)
- The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma (2015) (1)
- Myc/max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells. (1997) (1)
- Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx) (2013) (1)
- The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM (2015) (1)
- Glucocorticoid-Induced Apoptosis by Bcl-2 B in the Rescue of Multiple Myeloma Cells From κ Role of NF- (2013) (1)
- Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat (2015) (1)
- Predictive Biomarkers and Personalized Medicine Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR 3 C 1 (2012) (1)
- The Antimalarial Agent Artesunate Exerts Its Antimyeloma Activity By Affecting The Mitochondria and The Reactive Oxygen Status Of The Myeloma Cells and Its Efficacy Depends On Intracellular Bivalent Iron Levels (2013) (1)
- The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable (2003) (1)
- Abstract 1648: Primary myeloma plasma cells are capable of growth in adult, normal whole human bone marrow environment . (2013) (1)
- Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma (2016) (1)
- Modified Combat Removes Batch Effects from Myeloma Cell GEP–derived Risk Scores and Molecular Subgroup Assignment (2014) (1)
- Identification of Biomarkers Associated with MAF-Mediated Resistance to Proteasome Inhibitors in t(14;16) Multiple Myeloma (2015) (1)
- Research on Cellular Senescence: Present and Future Directions (1977) (1)
- Genotypic and phenotypic diversity of plasma cell myeloma (1988) (0)
- Intra-Tumoral Heterogeneity In Multiple Myeloma Gleaned From Gene Expression Profiling Analysis Of Plasma Cells and Bone Marrow Biopsies: Comparison Of Random Bone Marrow Samples and CT-Guided Fine Needle Aspirations Of MRI-Defined Focal Lesions (2013) (0)
- Mafb Protein Confers Primary Resistance of Myeloma to Proteasome Inhibitors (2014) (0)
- Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis (2013) (0)
- Comparing Gene Expression Profiling (GEP) Features Of Bone Marrow Biopsies (BMBx) Of Patients With Multiple Myeloma (MM) and Normal Donors (NL): 24 Microenvironment Specific Gene Probes Distinguish MM From NL (2013) (0)
- 18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials. (2012) (0)
- Paul bone Heparanase promotes the spontaneous metastasis of myeloma cells to (2004) (0)
- Can we cure Multiple Myeloma by 2020? Yes (2015) (0)
- myeloma therapy The syndecan-1 heparan sulfate proteoglycan is a viable target for (2013) (0)
- other imaging techniques and prognostic factors in multiple myeloma F18-fluorodeoxyglucose positron emission tomography in the context of (2011) (0)
- Reduced HMOX1 Expression in Myelomatous Bones Is Associated with Poor Survival and Its Induction Regulates Osteoclastogenesis and Osteoblastogenesis (2012) (0)
- Plasma adriamycin levels during remission induction therapy: RIA versus HPLC. (1986) (0)
- An Inborn Variation In The Anaplastic Lymphoma Receptor Tyrosine Kinase Gene (ALK) Increases Risk Of MAF (Musculoaponeurotic Fibrosarcoma Oncogene Homolog) High Expressing Myeloma (2013) (0)
- Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma (2015) (0)
- Lenalidomide Suppression of Multiple Myeloma Cell Proliferation Is Associated with Downregulation of LEF/TCF Activity (2012) (0)
- Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma (2015) (0)
- FISH and GEP Based Prediction of Chromosomal Translocation Identifies Myeloma Patients Who Do Not Benefit From Bortezomib (2012) (0)
- Molecular Subtyping and Risk Stratification for the Classification of Myeloma (2015) (0)
- Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2). (2006) (0)
- Histological and immunological evaluation of gnotobiotic C3H/He mice following i.v. administration of 8-aminoguanosine and 2'deoxyguanosine. (1985) (0)
- PF606 ADVERSE IMPACT OF PRIOR THERAPY ON TRANSPLANT OUTCOME IN MULTIPLE MYELOMA (2019) (0)
- MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2. (2006) (0)
- Mitogen-Activated Protein Kinase p38 Immature Dendritic Cells: Involvement of of Lipopolysaccharide on In Vitro Generation Novel and Detrimental Effects of (2003) (0)
- Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs “Discontinuous” Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM). (2005) (0)
- Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma (2018) (0)
- Abstract 4112: E-cadherin regulates cell adherence and β-catenin/TCF signaling in multiple myeloma. (2013) (0)
- Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease, (2011) (0)
- Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors (2018) (0)
- Inhibition of adenosine deaminase and purine nucleoside phosphorylase and T-cell function in germfree mice and human peripheral blood. (1985) (0)
- The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States (2016) (0)
- Healthy Donor Whole Bone Marrow Cells Preconditioned With Myeloma Patient Serum Support Long-Term Survival Of Primary Myeloma and Reveal Altered Microenvironmental Pathways (2013) (0)
- High CCN1 Levels Are Associated with Longer Progression-Free and Overall Survival in GEP-Defined High-Risk Myeloma (2012) (0)
- Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM) (2015) (0)
- Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival. (2010) (0)
- [Plasma cell myeloma. I. A new concept of disease biology]. (1991) (0)
- Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics. (2006) (0)
- Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance. (2005) (0)
- HMOX1 Is a Targeted Therapy for Myeloma-Induced Bone Disease. (2012) (0)
- in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities, (2013) (0)
- Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP). (2014) (0)
- Murine Models of Myeloma Bone Disease: The Importance of Choice (2010) (0)
- Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups (2012) (0)
- The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells (2019) (0)
- study of 169 patients single-agent thalidomide: identification of prognostic factors in a phase 2 Extended survival in advanced and refractory multiple myeloma after (2013) (0)
- Inhibition Of BTK Activity In Myeloma Cells Within a Supportive Microenvironment Promotes Their Growth But Suppresses Metastasis (2013) (0)
- Arkansas Autotransplant (AT) Experience with > 2500 Myeloma (MM) Patients: Follow-Up Extending to >15 Years. (2005) (0)
- Effects of cytosine arabinoside on rf/un murine myeloid leukemia cells. Abstr. (1979) (0)
- Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs (2012) (0)
- DKK 1 as a universal myeloma antigen DKK 1 IS A WIDELY EXPRESSED AND POTENT TUMOR-ASSOCIATED ANTIGEN IN MULTIPLE MYELOMA (2007) (0)
- Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression. (2012) (0)
- cell involvement Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B (2011) (0)
- Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse (2017) (0)
- Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival (2014) (0)
- Exomic microRNA Profiling of Bone Marrow Aspirate Plasma and Comparison with mRNA Profiles Used in the Clinical Management of Multiple Myeloma (2014) (0)
- Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3) (2012) (0)
- Human Placenta-Derived Adherent Stem Cells Prevent Bone Loss and Stimulate Bone Formation in Myelomatous Bones, and Suppress Growth of Primary Multiple Myeloma (2008) (0)
- [Plasma-cell myeloma. II. New developments in the diagnosis and treatment of the disease]. (1992) (0)
- Cytogenetic Features Of Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Asymptomatic Multiple Myeloma (AMM) (2013) (0)
- Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma (2018) (0)
- Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma (2014) (0)
- Role of Osteoclasts in Regulation of Human Hematopoietic Stem Cell Niche and Fate. (2004) (0)
- 47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma (2015) (0)
- Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma. (2005) (0)
- Fibroblast Activation Protein (FAP) Is a Critical Microenvironmental Survival Factor for Myeloma Plasma Cells. (2004) (0)
- N-Cadherin Expressing MM Cells Form Calcium-Dependent, Adherent Junctions That Likely Contribute to Focal Lesions and Nodular Growth of Multiple Myeloma Cells (2010) (0)
- Defining Risk of MGUS and AMM Progression to Myeloma By Ig Heavy-Chain FISH (2014) (0)
- Myeloma and Osteolytic Bone Disease: Is DKK1 All It Takes?. (2008) (0)
- Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes (2018) (0)
- Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma (2015) (0)
- JNK Regulates DKK1 Expression in Multiple Myeloma Cells. (2006) (0)
- MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma (2018) (0)
- Tumor idiotype antigen-specific immunization of myeloma marrow transplant donors (1998) (0)
- detected by multiprobe interphase FISH High incidence of chromosome 13 deletion in multiple myeloma (2013) (0)
- Surface Chemistry Proteomics and Biomarker Discovery in Multiple Myeloma. (2005) (0)
- Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms (2012) (0)
- The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis (2012) (0)
- Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma (2011) (0)
- Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy (2015) (0)
- Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM). (2012) (0)
- CKS1B, Mapping to an Amplicon on Chromosome 1q21 and over Expressed in Aggressive Disease, Regulates Multiple Myeloma Growth and Survival through p27 Kip1 -Dependent and Independent Mechanisms. (2006) (0)
- Human Placenta-Derived Adherent Cells Delivered Intralesionally Inhibit Myeloma Bone Disease and Tumor Growth, While Intravenously Are Capable of Trafficking to Myelomatous Bone. (2010) (0)
- PS1386 CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA (2019) (0)
- Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt (2014) (0)
- Conversion of Non-Secretory to Hyper-Secretory Myeloma: The Antithesis of the Common Pathway of Dedifferentiation with Myeloma Progression: A Case Study (2012) (0)
- Prevention of fetal gvhd following bone marrow transplantation by pre-treatment of the inoculum with anti-t-cell drugs. Abstr. (1983) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Joshua M. Epstein?
Joshua M. Epstein is affiliated with the following schools:
